Table 1.
Patient characteristics according to cabozantinib dose level
| Factor | Stat | cabozantinib, 20mg, N=12 | cabozantinib, 40mg, N=12 | cabozantinib, 60mg, N=3* | Total N=27 |
|---|---|---|---|---|---|
| Follow-up (months) | Median (IQR) | 21.8 (15.4,35.0) | 38.1 (17.1,41.8) | 55.8 (31.1,56.9) | 33.8 (16.9,43.2) |
| [3.6,60.4] | [7.4,58.5] | [6.3,58.0] | [3.6,60.4] | [3.6,60.4] | |
| Age at diagnosis (year) | Median (IQR) | 62 (59,66) | 60 (57,62) | 57 (55,59) | 60 (57,64) |
| Range | [50,74] | [49,68] | [53,61] | [49,74] | |
| Age at start of study (year) | Median (IQR) | 66 (61,72) | 62 (61,67) | 65 (60,68) | 64 (61,70) |
| Range | [52,76] | [53,75] | [56,71] | [52,76] | |
| Race (White) | N (%) | 12(100.0) | 11(91.7) | 3(100.0) | 26(96.3) |
| Baseline ECOG PS N (%) | 0 | 11(91.7) | 11(91.7) | 3(100.0) | 25(92.6) |
| 1 | 1(8.3) | 1(8.3) | 0(0.0) | 2(7.4) | |
| Gleason at Dx, N (%) | ≤6 | 0(0.0) | 1(8.3) | 1(33.3) | 2(7.4) |
| 7 | 2(16.7) | 2(16.7) | 0(0.0) | 4(14.8) | |
| 8–10 | 10(83.3) | 9(75.0) | 2(66.7) | 21(77.8) | |
| Baseline testosterone level (ng/dL) | Median (IQR) | 7 (0,10) | 11 (10,17) | 7 (7,7) | 9 (7,12) |
| Range | [0,16] | [7,24] | [7,7] | [0,24] | |
| Baseline PSA (ng/mL) | Median (IQR) | 31 (19,72) | 14 (2,47) | 8 (6,9) | 20 (6,45) |
| Range | [1,376] | [0,783] | [4,11] | [0,783] | |
| Prior docetaxel use | N (%) | 5(41.7) | 5(41.7) | 1(33.3) | 11(40.7) |
| Prior opiate use | N (%) | 5(41.7) | 6(50.0) | 1(33.3) | 12(44.4) |
| Visceral metastases | N (%) | 2(16.7) | 1(8.3) | 1(33.3) | 4(14.8) |
| LDH >1xULN, N (%) | Yes | 2(16.7) | 1(8.3) | 1(33.3) | 4(14.8) |
| No | 10(83.3) | 11(91.7) | 2(66.7) | 23(85.2) | |
| Normal Albumin (3.7–5.4 g/dL) | N (%) | 12(100.0) | 12(100.0) | 3(100.0) | 27(100.0) |
| HGB (<12.5 g/dL) N (%) | Low | 5(41.7) | 4(33.3) | 2(66.7) | 11(40.7) |
| Normal | 7(58.3) | 8(66.7) | 1(33.3) | 16(59.3) | |
| Alkaline Phosphatase (>118 U/L), N (%) | High | 4(33.3) | 4(33.3) | 0(0.0) | 8(29.6) |
| Normal | 8(66.7) | 8(66.7) | 3(100.0) | 19(70.4) |